Malondialdehyde can predict survival in hemodialysis patients

Authors

  • Crina Claudia Rusu
  • Simona Racasan
  • Ina Maria Kacso
  • Diana Moldovan
  • Alina Potra
  • Ioan Mihai Patiu
  • Dan Vladutiu
  • Mirela Gherman Caprioara

DOI:

https://doi.org/10.15386/cjmed-537

Keywords:

oxidative stress, hemodialysis, cardiovascular disease, survival, malondialdehyde

Abstract

Background and aims. Cardiovascular (CV) disease is the leading cause of morbidity and mortality in hemodialysis (HD) patients. Kidney disease is associated with increased oxidative stress (OS), a nontraditional CV risk factor. Few studies evaluate the effect of OS markers on CV events (CVE) and survival in HD patients. The aim of this study is to examine potential determinants of OS markers and their predictive role on survival and CV morbidity and mortality in HD patients during a long-term follow-up (108 months).  

Methods. We conducted an analytical cross-sectional prospective observational study, carried on a cohort of randomly selected HD patients. We registered in 44 HD patients baseline characteristics, OS markers, mortality and CVE over a period of 108 months and we used statistical analysis (descriptive, Kaplan-Meier, univariate and multivariate Cox model) for interpretation.

Results. Bound malondialdehyde (bMDA) was positively correlated with serum calcium, protein carbonyls (PC) were inversely correlated with diastolic blood pressure (DBP) and directly correlated with ferritin, NOx was directly correlated with ceruloplasmin) and serum albumin. Of the measured OS markers only bMDA was related to survival (HR=3.29 95% CI (1.28-8.44), p=0.01), and approached statistical significance in the effect on CV mortality (HR=2.85 95% CI (0.88-9.22), p=0.07). None of the measured OS markers was associated with CVE.

Conclusions. bMDA has a strong predictive value on survival in HD patients in a long-term follow-up (9 years). Its value is correlated with CV mortality but is not a predictor of CV events. Regular assessment of MDA in HD patients and the development of strategies aimed at reducing oxidative stress in these patients might be beneficial.

Author Biographies

Crina Claudia Rusu, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca

Nephrology

Simona Racasan, Nefromed Dialysis Center, Cluj-Napoca

Dialysis

Ina Maria Kacso, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca

Nephrology

Diana Moldovan, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca

Nephrology

Alina Potra, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca

Nephrology

Ioan Mihai Patiu, Nefromed Dialysis Center Cluj-Napoca

Dialysis

Dan Vladutiu, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca

Nephrology

Mirela Gherman Caprioara, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca

Nephrology

Downloads

Additional Files

Published

2016-04-21

How to Cite

1.
Rusu CC, Racasan S, Kacso IM, Moldovan D, Potra A, Patiu IM, Vladutiu D, Gherman Caprioara M. Malondialdehyde can predict survival in hemodialysis patients. Med Pharm Rep [Internet]. 2016 Apr. 21 [cited 2025 Oct. 6];89(2):250-6. Available from: https://medpharmareports.com/index.php/mpr/article/view/537

Issue

Section

Original Research